In the present study, we observed an equal distribution of NPM1 and IDH2 mutations between BCL-2− and BCL-2+ AML patients, suggesting that BCL-2 positivity is not a prerequisite for obtaining a response to venetoclax therapy. The gene discussed is NPM1; the disease is acute myeloid leukemia.